GRI Bio Files 8-K on Financials
Ticker: GRI · Form: 8-K · Filed: Mar 17, 2025 · CIK: 1824293
Sentiment: neutral
Topics: financial-reporting, company-update
TL;DR
GRI Bio dropped an 8-K on financials, check it out.
AI Summary
GRI Bio, Inc. filed an 8-K on March 17, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The company, formerly known as Vallon Pharmaceuticals, Inc. until a name change on April 24, 2023, is incorporated in Delaware and headquartered in La Jolla, California.
Why It Matters
This filing provides an update on GRI Bio's financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not appear to contain any significant new risks or material adverse events.
Key Players & Entities
- GRI Bio, Inc. (company) — Registrant
- Vallon Pharmaceuticals, Inc. (company) — Former company name
- 20250317 (date) — Filing date
- 20230424 (date) — Date of name change
- 20200910 (date) — Date of prior name change
- Delaware (jurisdiction) — State of incorporation
- La Jolla, CA (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on GRI Bio, Inc.'s results of operations and financial condition, as well as to provide financial statements and exhibits.
When was GRI Bio, Inc. previously known by another name?
GRI Bio, Inc. was formerly known as Vallon Pharmaceuticals, Inc. until a name change on September 10, 2020, and then GRI BIO, Inc. until April 24, 2023.
In which state is GRI Bio, Inc. incorporated?
GRI Bio, Inc. is incorporated in Delaware.
What is the business address of GRI Bio, Inc.?
The business address of GRI Bio, Inc. is 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037.
What is the filing date of this 8-K report?
The filing date of this 8-K report is March 17, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 17, 2025 regarding GRI Bio, Inc. (GRI).